亮丙瑞林联合米非司酮治疗子宫腺肌瘤对患者激素水平的改善作用  

The improvement effect of leuprolide plus mifepristone on hormone levels in patients with adenomyoma

作　　者：吴鹤 Wu He(Department of Obstetrics and Gynecology,Baicheng Central Hospital,Baicheng 137000,China)

机构地区：[1]白城中心医院妇产科,吉林白城137000

出　　处：《实用妇科内分泌电子杂志》2021年第32期44-46,共3页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的 分析亮丙瑞林联合米非司酮治疗子宫腺肌瘤对患者激素水平的改善作用。方法 选取62例子宫腺肌瘤患者为研究对象,按照双盲法将患者分为A组(采用亮丙瑞林治疗)与B组(采用亮丙瑞林联合米非司酮治疗),每组31例。对比两组治疗效果。结果 B组治疗总有效率93.55%高于A组的74.19%,差异有统计学意义(P<0.05);B组不良反应发生率9.68%高于A组的6.45%,但差异无统计学意义(P>0.05);B组治疗后雌二醇(E_(2))、促黄体生成素(LH)、孕酮(P)、卵泡刺激素(FSH)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、胰岛素样生长因子-1(IGF-1)、表皮细胞生长因子(EGF)、子宫体积及肌瘤体积均优于A组,差异有统计学意义(P<0.05)。结论 亮丙瑞林联合米非司酮治疗子宫腺肌瘤患者可改善临床症状,恢复激素水平。Objective To analyze the improvement of hormone level of patients with adenomyoma treated with lepreteriline combined with mifepristone. Methods 62 patients with adenomyoma of uterus were selected as the study subjects. According to the double-blind method, the patients were divided into group A(treated with lepraline) and group B(treated with lepraline combined with mifepristone), with 31 cases in each group. The therapeutic effect of the two groups was compared. Results The effective rate of group B was 93.55% higher than that of group A(74.19%), and the difference was statistically significant(P<0.05). The incidence of adverse reactions in group B was 9.68% higher than that in group A(6.45%), but the difference was not statistically significant(P>0.05). After treatment, estradiol(E_(2)), luteinizing hormone(LH), progesterone(P), follicle-stimulating growth hormone(FSH),hypersensitive C-reactive protein(hs-CRP), tumor necrosis faction-α(TNF-α), insulin-like growth faction-1(IGF-1), epidermal cell growth factor(EGF), uterine volume and fibroid volume were all superior in group B Group A, the difference was statistically significant(P<0.05). Conclusion Lepraline combined with mifepristone in the treatment of adenomyoma patients can improve clinical symptoms and restore hormone levels.

关 键 词：亮丙瑞林 米非司酮 子宫腺肌瘤 治疗效果 临床指标 

分 类 号：R737.33[医药卫生—肿瘤]